Durlobactam sodium salt is primarily used in combination with sulbactam for the treatment of serious bacterial infections, particularly those caused by multidrug-resistant Acinetobacter species. It functions as a beta-lactamase inhibitor, effectively restoring the activity of beta-lactam antibiotics against resistant strains by blocking the enzymes that bacteria use to inactivate these antibiotics. This combination is especially valuable in hospital settings where infections with carbapenem-resistant Acinetobacter baumannii (CRAB) are prevalent. Due to its targeted mechanism, durlobactam enhances the efficacy of existing antibiotics, offering a critical option for treating life-threatening infections in intensive care units and among immunocompromised patients. Its development addresses the growing need for novel strategies to combat antimicrobial resistance in Gram-negative pathogens.